Shared Accountability Is No Accountability

Pharma’s AI Retrofit Ceiling named the structural reason that established pharma can’t retrofit AI onto a legacy commercial model and has to rebuild instead. The next question is operational, and it’s the question most rebuild conversations stall at without ever quite asking it out loud.

The AI-native rebuild of pharma commercial sits with what is typically four operational SLT seats: the Head of Commercial (CCO), the Chief Digital / Analytics Officer (CDO), the Head of Value & Access (CMAO), and the Head of Medical Affairs (CMO). All four contribute - but there can only be one owner. Until that ownership question gets answered plainly (in writing, in a room, with a name attached) the rebuild work doesn’t materialize, no matter how good the strategy is or how many pilots are running. Most orgs stall at the ownership question before they ever get to the work.

I’ve watched the same scene play out three times within Top-25 pharma in the last two years. The CCO opens a working session on AI-native commercial operations, with the CDO, CMO, and CMAO at the table. By the third slide, everyone agrees the rebuild is necessary. By the fifth, somebody asks who’s accountable for the outcome. Three pairs of eyes go to the CCO. The CCO looks at the CDO. The CDO looks at the deck. The room settles on “shared accountability across the leadership team,” and the meeting wraps. Six months later the pilot pipeline is intact, the data layer hasn’t moved, and a third-party firm has been engaged to run a “cross-functional alignment workshop.” Forrester puts the average CCO tenure at roughly three to four years across pharma, compressed from longer windows a decade ago. If “shared accountability” is the answer, the CCO who walked into that room is statistically unlikely to be the CCO who watches a rebuild materialize.

This is the structural problem, stated plainly:

The topic worth discussing here is narrow on purpose. Benchling and the biotech-startup AI rebuild crowd are answering a different question. They’re designing commercial functions from scratch, not renegotiating ones that already employ thousands of people. Eric Topol’s clinical-AI work sits at the bedside, where the seats are physicians and FDA reviewers. And the generic enterprise-AI commentary that fills LinkedIn assumes a commercial org that doesn’t carry medical-commercial firewalls, MLR review queues, or pharmacovigilance obligations. Established pharma organizations carries all of that, which is why “who owns the rebuild” lands as a specific question with four named seats, not an abstract one about AI strategy.

Why retrofit didn’t force this question, and rebuild does

In a retrofit, ownership is implicit. Whoever has the AI mandate owns the AI work, usually the CDO, sometimes a Chief AI Officer, occasionally the CCO. Other functions cooperate at the margins. The brand team gets a content-generation tool, Medical Affairs gets a review-assist tool, the field force gets yet another next-best-action recommendation. Nobody’s job description changes. Nobody’s accountability lines redraw. The retrofit motion was specifically designed to leave territory intact.

Rebuild is the opposite. The AI-Native Rebuild renegotiates the seams between functions - particularly the seams in which accountability is undefined. It asks the data layer underneath every commercial decision to be different, which means every function that generates or consumes that data has to redesign its workflow. The CCO’s accountability lines change. The CDO’s mandate changes. The CMAOs and the CMOs job description changes. None of those people signed up for those changes when they took the seat, and most of them won’t accept these changes implicitly. They need them named, sponsored, and resourced.

That’s the structural reason “shared accountability” answers fail. Cross-functional steering committees are useful for coordination. They are not substitutes for ownership, and the moment the work hits political friction (which it always will, particularly as quarters come to a close), shared accountability across four senior executives reverts to no accountability at all.

Bain’s commercial-AI commentary names the function-level shift: pharma commercialization in the age of AI requires an operating-model shift, not a tooling refresh. The next level down (which seat owns what) is where the actual political horse-trading happens. And it’s the level most consulting engagements will never quite get to, because the level above (the strategy slides, org charts, 3 year plans) is easier to deliver against and reduces exposure to risk (in this case, the continuity of the engagement) than the level below (the roles and responsibilities, accountability measures, delivery of tangible impact through performance management over the next 6-18 months).

Four seats, two states each

Each of the four seats shows up differently in the retrofit motion than they will in the rebuild. Defining the difference is a precondition for naming the ownership.

Commercial

In the retrofit, the CCO managed an investment portfolio. Approve the pilots, review the pipeline, ask why production is taking so long, rotate out before anything ships at scale.

In the rebuild, the CCO is the architect of the operating-model commitment the rest of the organization builds toward. The commitment has to be specific, written, and signed before the next budget cycle. Not “deploy AI across the commercial organization.” Something like: “By Q3 2027, HCP-engagement orchestration runs on continuous-decisioning data architecture across [therapy areas], with field and brand leaders quarterly review measured against actual engagement as a temporary leading indicator and NBRx growth replacing that in 1-2 quarters, not execution against plan.” Plain language, in writing, before October. The commitment lives at the commercial-model layer; the customer-engagement motion (HCP reach, content velocity, MLR choreography) is where it has to prove itself in lived experience.

The orgs whose CCOs are writing this kind of commitment in plain language are moving. Roche’s senior leadership has been naming AI-driven decisioning across the commercial organization with specific commitments under CEO Thomas Schinecker. Eli Lilly has paired AI-driven HCP engagement with operating-model changes, not just tooling. The orgs whose CCOs are still managing the pilot portfolio are commissioning their sixteenth pilot.

The hard part of this seat isn’t naming the commitment. It’s confronting that the data layer underneath the commitment may not be one the CDO has been funded to build, which means the commitment forces a conversation with the CFO that the retrofit-era CCO never had to have. Most CCOs sitting in this question right now are deferring it because the political capital required to commission the data layer is the same capital required to defend the pilot count. You have to say the trade-off out loud to the CEO, CFO, and others on the SLT if you ever want to confront it.

Digital, Data and Analytics

In the retrofit, the CDO greenlights analytics and digital product work as commercial peers request it, builds the team to deliver against the backlog, and watches model after model perform in development and stall in production because the data foundation can’t carry continuous AI workloads.

In the rebuild, the CDO refuses model work that lands on a pre-AI data layer, and commits the data layer as the deliverable rather than as enabling work. Pick one commercial data domain (HCP engagement signal, content compliance choreography, or commercial analytics) and rebuild it AI-native before the next model or use case lands on top of it. The data foundation IS the project and it needs to ship before a model or use case lands on top. In fact, you will find that as more data is converted into an AI native foundation, your engineers’ agentic coding tools will get faster and smarter in delivering the use cases.

That said, this is the hardest political move of the four. Saying no to use case enablement feels like saying no to the AI agenda. It isn’t. It’s saying no to the next fifteen pilots that would have died in production, in favor of the one data foundation rebuild that makes the next fifteen ship. Most CDOs can name the architecture work that needs to happen. Most can’t name the political conditions under which they could commission it.

The evidence that the work is fundable is hiding in plain sight. Novartis’s data42 is platform-level investment, not pilot-level. Roughly two million patient-years of data across more than 200 internal projects. AstraZeneca’s CFO Aradhana Sarin has framed AI-related investment as productivity infrastructure rather than a pilot pipeline. Forrester’s CDO mandate research shows roughly two-thirds of CDOs report commercial peers want models faster than the data foundation can support, and roughly one-third report CFOs willing to fund foundational data work as a multi-year line item rather than a pilot expense. The mandate gap is the political opportunity. CDOs who name it in writing, with a specific architecture decision attached, convert it into a budget defense rather than absorbing it as tension.

If you’re in this seat, the question is whether your real job for the next two quarters is delivering the next model or refusing it. The CDO who waits for permission gets a sixteenth pilot. The CDO who names the trade-off in writing, with the architecture decision attached, converts the absorbed tension into a budget conversation the CFO can fund, but only if the CCO has named the operating-model commitment that gives the architecture decision its shape.

Medical Affairs

In the retrofit, the CMO owns the gates at the end of the commercial workflow. Review assets, adjudicate medical-legal-regulatory questions, add reviewers when volume grows, become the chokepoint surfaced at every QBR. Field medical is an expectation and requirement for scientific discussions - but ultimately a cost center to be cut when budget pressure mounts. The metrics are operational: MSL interactions logged, review turnaround time, KOL engagement frequency. None of those metrics connect medical activity to the thing medical exists to influence - whether patients get better outcomes.

In the rebuild, the Medical Affairs head owns the front of the most valuable data pipelines in the organization. MSLs are in the field 18 months ahead of commercial when a drug launches - they are the front line in generating data and insights that will inform the commercial motion. They own high-credibility relationships with KOLs and opinion leaders. No, Medical can’t direct commercial or vice versa - but they can and should collaborate in ways that are mutually beneficial. In the rebuild, the CMO and CCO work together to define solutions for delivering consistent, relevant HCP engagement - because you can’t force fit a commercial solution into medical and expect it to work well (if you don’t believe that, go ask an MSL what they think about Veeva CLM).

The transformation that matters most: AI agents continuously analyze all data - interactions, prescribing patterns, patient journey signals, treatment adherence, clinical outcomes - in a clean room to optimize the impact of medical activity. Not against NBRx. Against patient outcomes, guideline adherence, and scientific amplification. The MSL who walks into a KOL meeting in the rebuild isn’t carrying a call plan designed by the commercial team - they’re carrying insights generated from a continuous analysis of how that KOL’s patients are actually doing, what evidence gaps exist in that therapeutic area, and where guideline adherence is breaking down in that geography. The conversation becomes clinically relevant because the data underneath it is clinically relevant.

In the rebuild, Medical Affairs is no longer a cost center. It’s an ROI-positive driver of credible scientific brand equity, the tip of the spear in pre-launch to create the conditions for commercial success, and the leader of a corporate mission to drive improved patient outcomes. The Medical Affairs head who can show the board a direct line between MSL engagement patterns and patient-outcome improvements in specific therapy areas has a budget defense that the retrofit-era CMO never had. The one who can’t show the patient impact is still defending headcount against a spreadsheet that shows cost-per-interaction.

The second structural shift in this seat is the MLR transformation. In the AI-native world, MLR moves to the front of the content workflow rather than gating it at the back. Medical works with legal / regulatory / compliance to define semantic and business rules. MLR has both gradations of risk and confidence (0 - 10) and memory (initially seeded with a bank of pass/fail examples that grows anytime there is manual intervention). All content modules get reviewed by AI. All modules approved by AI are reviewed by a human once. Human decisions get recorded in the memory bank. When the same approved content is re-used somewhere else, in combination with other pre-approved content, the rules determine the risk in the context of re-use and re-assembly. The volume math decompresses. Medical Affairs stops being the chokepoint and becomes the rules-author.

The volume math makes this structurally significant. Large pharma brands run between $200M and $800M in DTC spend annually, with content variant counts roughly doubling year over year as personalization tooling matures. The MLR pipeline that handled 500 assets per quarter in 2020 is being asked to handle 50,000 in 2027. The retrofit math - more reviewers, faster review tools - doesn’t scale. The rebuild math does, but only if Medical Affairs authors a content typology that names what’s rule-eligible and what requires human judgment.

ACMA’s 2024-2025 pulse on medical affairs transformation shows roughly 60% of medical affairs heads now name scope expansion into commercial-content rule-authoring as a strategic priority, up from roughly 20% two years prior. GSK and Bristol Myers Squibb have made public commitments to AI-augmented medical affairs work that includes operating-model changes, not just review tooling. AbbVie’s medical affairs leadership has surfaced specific commitments around content typology in trade press, framed as the move that lets medical affairs scale alongside the commercial AI agenda rather than gate it.

The thing this seat carries that the other three don’t: whether the rebuild reads to the medical team as an elevation of the patient mission or as loss of medical-commercial independence. Some will read the patient-outcomes measurement as commercial encroachment. Others will read the typology move as a demotion of nuanced judgment - fewer assets crossing their desk, less authority over what ships, the AI doing work that used to define their job. If the Medical Affairs head doesn’t walk the team through the framing explicitly - that this is medical expanding into outcome measurement and scientific strategy, not commercial absorbing medical into a content factory - the pilot produces passive resistance that looks like methodological concern and actually is identity protection. The cost of getting the framing wrong is six months of dressed-up obstruction inside what should have been the rebuild’s fastest-moving function.

Value and Market Access

In the retrofit, the CMAO runs the access machine on a product-by-product basis. Negotiate payer contracts, manage formulary position, commission HEOR studies to defend price, monitor gross-to-net erosion on a quarterly lag. The data underneath the access strategy refreshes on the same cycle as everything else in the legacy commercial model - quarterly snapshots, annual contract reviews, claims data that’s three to six months old by the time it reaches the analytics team. The AI tooling the CMAO gets in the retrofit is a faster version of the same workflow: predictive models for formulary risk, automated prior-authorization support, contract-optimization dashboards. Nobody’s accountability changes. The access strategy still sits downstream of launch, reacting to payer signals rather than shaping the commercial model around them.

In the rebuild, the CMAO becomes the architect of the evidence-to-access pipeline - the continuous layer that connects clinical value to commercial access in real time, not on a quarterly lag. Three things change structurally:

First, the evidence pipeline becomes continuous. HEOR stops being a 12-to-18-month study commissioned to defend a pricing decision that’s already been made. It becomes a real-time evidence-generation engine fed by the same AI-native data layer the CDO is building. Real-world evidence doesn’t arrive as a report - it arrives as a continuously updating signal that informs payer strategy, formulary defense, and patient-access interventions as market conditions shift.

Second, contract optimization moves from lagging to leading. The legacy access model optimizes rebates and contracting terms against historical claims data. The rebuild model runs continuous contract-performance analytics against real-time utilization signals - which means the CMAO can identify gross-to-net erosion and formulary-position shifts as they’re happening, not three months after the fact. The difference between a CMAO who catches a formulary exclusion signal in week two and one who catches it in quarter two is measured in millions of dollars of revenue exposure per product.

Third, patient access becomes predictive rather than reactive. Prior-authorization workflows, patient-assistance programs, hub services - all of it currently operates as exception handling after a prescription is written. In the rebuild, the AI-native access model predicts access barriers before they materialize: which patients will hit step-therapy requirements, which payers are tightening formulary criteria, where co-pay accumulator programs will create affordability gaps. The CMAO’s team stops managing access exceptions and starts designing access architecture.

The evidence that the access function is being repositioned is visible in the tooling investments and the talent shifts. IQVIA’s May 2025 acquisition of WhizAI added conversational AI analytics to its market access portfolio - spanning gross-to-net orchestration, formulary-position tracking, and market access planning - signaling that the largest commercial-data vendor in pharma sees AI-native access analytics as a platform-level capability, not a feature. Amgen has deployed an AI agent called Eva - built with Infinitus - to handle payer benefit verification, compressing a process that used to take five days to under 48 hours. Eva uses NLP and machine learning to interpret payer data and continuously improves through a payer intelligence knowledge graph. Russell Reynolds published a 2025 study on the elevation of the Chief Market Access Officer to the C-suite, noting that the most effective CMAOs are no longer functional specialists but business strategists who shape company-wide decisions - and that organizations positioning market access on equal footing with commercial and medical leadership gain a critical competitive edge.

The scale of the problem makes the data dependency unavoidable. Total gross-to-net reductions for all brand-name drugs reached $356 billion in 2024. An estimated 2 to 3 percent of rebate value - $10 to $15 million for a manufacturer paying $500 million in annual rebates - is compromised due to formulary compliance issues alone. The CMAO who catches a formulary exclusion signal in week two rather than quarter two is defending revenue exposure that compounds fast. But the real-time monitoring that makes that possible runs on the same data layer the CDO is commissioning. If the CDO’s architecture decision doesn’t explicitly scope the access data domain - claims data, formulary-position signals, patient-journey analytics - the CMAO inherits a data layer designed for HCP engagement and field operations but structurally unable to carry continuous access workloads. The CMAO has to be in the room when the CDO’s architecture decision is scoped, not downstream of it.

The CMAO who waits for the data layer to arrive gets a dashboard. The CMAO who names the access data domain as a co-equal scope in the CDO’s architecture decision gets a pipeline. The difference shows up twelve months later as the gap between quarterly access reporting and continuous formulary defense.

The ownership question, named plainly

Four roles. Four contributions. Four distinct artifacts. The question is which one owns the outcome.

The temptation is to say all four. Stand up a cross-functional steering committee, declare shared accountability, hire a third-party firm to facilitate the alignment, hire a third-party firm to recommend the four roles “work together more effectively.” The temptation fails for the structural reason at the top of this piece. Shared accountability across four senior executives, each with their own function, staff, incentives, and political constraints, defaults to no accountability the moment the work hits friction. Friction is guaranteed, because rebuild work renegotiates territory, and renegotiation produces resistance from the function below the executive: the MLR reviewers, the data engineers, the field force, the access analysts. Without an explicit owner, every function’s resistance routes to “we need more cross-functional alignment,” which routes to another working session, then another alignment workshop, then nothing shipping.

The recommendation, then:

The CCO is accountable for whether the rebuild ships on the date the operating-model commitment names. The CDO is accountable for whether the data layer can carry continuous AI workloads by the date the architecture decision names. The CMO is accountable for whether patient-outcomes measurement is operational and the content typology pilots successfully by the date the typology names. The CMAO is accountable for whether the evidence-to-access pipeline is continuous by the date the access architecture names. The CCO owns the integrated outcome.

The rebuild ships only when the CCO names the operating-model line item AND the CDO commits the data layer as the deliverable, in the same room, in writing, on the same date. Not “shared accountability.” Not “cross-functional steering committee.” Not “alignment workshop.”

The choreography

Once ownership is named, the four artifacts have a sequence, and inverting it is one of the more common ways the rebuild stalls.

The Medical Affairs head’s content typology and patient-outcomes measurement framework drafts first, because the typology is the fastest artifact to produce and the outcomes framework defines what the data layer needs to carry for medical. The CMAO’s evidence-to-access architecture scopes second, because it needs to name the access data domain alongside the CDO’s architecture decision - these two are co-dependent. The CDO’s architecture decision document drafts third, because it needs the content-rules map, the outcomes-measurement requirements, and the access data domain to know what it’s building toward. The CCO’s operating-model commitment drafts fourth, because it needs all three prior artifacts to be defensible at the next budget submission.

Reverse the order and the rebuild stalls. CCOs who write the operating-model commitment without the prior three produce a commitment the function below them won’t accept. CDOs who lock architecture without the content-rules map or the access data domain produce a data foundation that serves one function and has to be rebuilt for the others twelve months in. CMAOs who wait for the data layer to arrive before scoping the evidence pipeline get a dashboard, not a pipeline.

That’s the political-reality reason most rebuilds stall in the choreography rather than the strategy. Each seat has internal deadline pressure that produces a strong incentive to lock its artifact before the upstream artifacts are done. The lock looks like progress. The lock is rework debt that compounds. The orgs that get the choreography right are the ones whose four seats have agreed to the sequence explicitly, with named hand-off dates, before any seat starts drafting.

The gain-loss math, named honestly

The retrofit motion preserved territory. The rebuild reshapes it. The gain-loss math is worth naming explicitly, because if it isn’t named the resistance shows up later anyway:

The CCO gains accountability for cross-functional operating-model commitments, not just commercial revenue. The CCO loses the ability to delegate the AI agenda to the CDO and stay above the fray. The board will not accept “the data team didn’t deliver” as explanation for a missed commitment the CCO authored.

The CDO gains authority over architecture decisions that affect commercial productivity. The CDO loses the ability to greenlight model work that lands on pre-AI data. Saying no to commercial peers, in a way that previously would have been escalated to the CCO and reversed, becomes the precondition for the rebuild rather than the obstacle to it.

The CMO gains a direct, measurable connection between medical activity and patient outcomes - the budget defense that transforms medical from cost center to strategic function. The CMO also gains the content-typology authorship that unlocks AI-scale content velocity. The CMO loses the operational insularity that defined the seat for two decades. Patient-outcomes measurement requires data integration across medical-commercial boundaries, and the typology work puts medical at the center of the content pipeline rather than at the gate. Both shifts require the CMO to lead the team through a framing conversation about what medical becomes, not what medical gives up.

The CMAO gains a continuous evidence-to-access pipeline that turns value & access from a reactive function into a strategic one. The CMAO loses the ability to operate the access machine on a product-by-product quarterly cycle - the rebuild demands real-time integration with the CDO’s data layer and explicit co-scoping of the access data domain. The transition requires the CMAO to be in architectural conversations they were never previously invited to.

Each seat is being asked to take on accountability they didn’t have. The political cost has to be named, by the CCO, in the same room where ownership is named.

The decision

Five parts, each with a calendar:

1. 01

   Name the owner of the outcome

   That’s the CCO. If the CCO won’t name themselves as accountable for the integrated outcome, the rebuild will not ship. Surface this to the CEO if necessary. Cost of waiting: another twelve months of pilots commissioned into the same operating model that ate the last fifteen.

2. 02

   Name the owner of the data layer

   That’s the CDO. If the CDO won’t commit the data layer as the deliverable rather than as enabling work, the rebuild will not ship. Cost of waiting: another year of model work that fails in production.

3. 03

   Name the owner of patient-outcomes measurement and the content typology

   That’s the Medical Affairs head. If the CMO won’t build the outcomes-measurement framework and author the content typology before the CDO’s architecture locks, the rebuild ships without the two artifacts that make medical strategic rather than operational. Cost of waiting: medical stays a cost center, the MLR queue breaks under AI-scale volume, and MSL activity continues to be measured in interactions logged rather than patient outcomes influenced.

4. 04

   Name the owner of the evidence-to-access pipeline

   That’s the CMAO. If the CMAO won’t name the access data domain as co-equal scope in the architecture decision, the rebuild ships a data layer that serves HCP engagement but not access - and the evidence pipeline stays quarterly. Cost of waiting: twelve more months of lagging payer signals and reactive formulary defense.

5. 05

   Name the date

   Most established pharma commercial orgs run on October budget submission, January launch, Q2 review, Q4 reset. The artifacts have to be signed before October if the rebuild is going to enter the next budget cycle. Miss October and it’s twelve more months under the ceiling.

The orgs that answer all five move. The orgs that don’t commission their sixteenth pilot.

Two questions, then. The first locates you on the Retrofit Ceiling as a structural matter, covered in the first piece. The second locates you on the Ownership Question as the seat you’re in:

Which of the four seats are you in, and if you’re the CCO, are you ready to write the operating-model commitment in plain language before October?

If you’ve read this far and the scene at the top of this piece sounded familiar, book a working session with Sundar. We’ll work through the rebuild dynamics in your org and what the first 90 days look like.

— Sundar

Next in the series: the chair that doesn’t exist yet. Why the seats that successfully lead the AI-native rebuild in 2027 won’t be the seats that led the digital transformation, and what the new C-suite role looks like on the org chart.

Sources

1. Forrester Research, State of Commercial Leadership in Pharma 2025: CCO tenure compression to 3-4 years average across pharma over the last decade.
2. Bain & Company, Pharma Commercialization in the Age of AI and Active Patients (2025).
3. Roche, public earnings commentary 2024-2026 on AI-driven decisioning across the commercial organization under CEO Thomas Schinecker. Q3 2025 / Q4 2025 earnings call transcripts.
4. Eli Lilly, public commitments on AI-driven HCP engagement and operating-model changes. 2025 commercial-organization commentary in earnings calls and trade press.
5. Novartis, data42 platform: public reporting on aggregation of approximately two million patient-years of data across more than 200 internal R&D and commercial projects.
6. AstraZeneca, CFO Aradhana Sarin’s investor commentary 2025 on generative AI as productivity infrastructure across the organization. Q3 2025 / Q4 2025 earnings transcripts.
7. Forrester Research, CDO Mandate Alignment in Life Sciences 2025: roughly two-thirds of CDOs report commercial-peer pressure for faster model delivery; roughly one-third report CFO willingness to fund foundational data work as a multi-year line item.
8. Statista / Kantar Media / Nielsen IMS Health, public DTC pharma marketing spend data 2024-2025. Large pharma brand DTC spend ranges $200M-$800M annually; content variant counts approximately doubling year over year.
9. PharmExec, Brand Director Survey 2025-2026: roughly 40% of respondents name “redesigning content review for AI-scale volume” as top operating concern, up from roughly 12% in 2023.
10. ACMA (Accreditation Council for Medical Affairs), Medical Affairs Transformation Pulse 2024-2025: roughly 60% of medical affairs heads name scope expansion into commercial-content rule-authoring as strategic priority.
11. GSK and Bristol Myers Squibb, public 2025 commitments on AI-augmented medical affairs operating-model changes. GSK Q3 2025 / BMS Q4 2025 earnings transcripts and trade press.
12. AbbVie medical affairs leadership commentary in MM+M / PharmExec trade press on content typology framework as strategic move enabling medical affairs to scale alongside commercial AI agenda.
13. IQVIA, WhizAI acquisition (May 2025): conversational AI analytics added to market access portfolio spanning gross-to-net orchestration, formulary-position tracking, and market access planning.
14. Amgen, Eva AI agent built with Infinitus for payer benefit verification. Public case study: benefit verification compressed from five days to under 48 hours using NLP, ML, and payer intelligence knowledge graph.
15. Russell Reynolds Associates, The Rise of the Chief Market Access Officer (August 2025): elevation of CMAO to C-suite; organizations positioning market access on equal footing with commercial and medical leadership gain competitive edge.
16. Drug Channels / Pharmaceutical Commerce, gross-to-net reporting 2024: total gross-to-net reductions for all brand-name drugs reached $356 billion.
17. Pharmaceutical Commerce, rebate leakage analysis: estimated 2-3% of rebate value compromised due to formulary compliance issues.